• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见的转甲状腺素蛋白淀粉样变性病Glu89Lys(p.Glu109Lys)的多系统表现:一名东亚女性的病例报告

Multisystemic manifestations of a rare Glu89Lys (p. Glu109Lys) transthyretin amyloidosis: a case report of an East Asian female.

作者信息

Huang Linhuan, Zhou Houshi, Chen Junling, Fang Ting, Lin Qi

机构信息

Department of Neurology, Shantou Central Hospital, 114 Waima Road, Shantou, Guangdong Province, China.

出版信息

BMC Neurol. 2025 Oct 17;25(1):430. doi: 10.1186/s12883-025-04392-1.

DOI:10.1186/s12883-025-04392-1
PMID:41107809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12532868/
Abstract

BACKGROUND

Transthyretin amyloidosis (ATTRv) presents with highly variable, multisystem phenotypes, complicating diagnosis.

CASE PRESENTATION

We describe a diagnostically challenging case of ATTRv caused by the rare Glu89Lys (p. Glu109Lys) variant in an East Asian female-the first reported instance in this ethnic group. The patient exhibited a complex multisystem phenotype spanning progressive axonal sensorimotor polyneuropathy with autonomic dysfunction, cerebral infarction, hypertrophic cardiomyopathy, vitreous opacities, and unexplained cachexia, culminating in a 4-year diagnostic odyssey. The lack of clinical suspicion delayed definitive diagnosis, ultimately achieved through combined tissue biopsy confirming amyloid deposits and targeted genetic sequencing confirming Glu89Lys variant.

CONCLUSION

Our findings highlight the imperative for heightened clinical vigilance and early utilization of multimodal diagnostic strategies in suspected ATTRv cases.

摘要

背景

转甲状腺素蛋白淀粉样变性(ATTRv)具有高度可变的多系统表型,使诊断变得复杂。

病例报告

我们描述了一例具有诊断挑战性的ATTRv病例,该病例由罕见的Glu89Lys(p.Glu109Lys)变异引起,患者为一名东亚女性,这是该种族群体中首次报告的病例。患者表现出复杂的多系统表型,包括伴有自主神经功能障碍的进行性轴索性感觉运动性多神经病、脑梗死、肥厚型心肌病、玻璃体混浊和不明原因的恶病质,最终经历了4年的诊断历程。临床怀疑的缺乏延迟了明确诊断,最终通过联合组织活检证实淀粉样沉积物以及靶向基因测序证实Glu89Lys变异得以实现。

结论

我们的研究结果强调了在疑似ATTRv病例中提高临床警惕性和早期采用多模式诊断策略的必要性。

相似文献

1
Multisystemic manifestations of a rare Glu89Lys (p. Glu109Lys) transthyretin amyloidosis: a case report of an East Asian female.罕见的转甲状腺素蛋白淀粉样变性病Glu89Lys(p.Glu109Lys)的多系统表现:一名东亚女性的病例报告
BMC Neurol. 2025 Oct 17;25(1):430. doi: 10.1186/s12883-025-04392-1.
2
Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center.遗传性转甲状腺素蛋白淀粉样变性的遗传和临床特征:日本一家转诊中心的十年经验
Orphanet J Rare Dis. 2025 Sep 2;20(1):474. doi: 10.1186/s13023-025-04006-6.
3
Patisiran in ATTRv amyloidosis with polyneuropathy: "PatisiranItaly" multicenter observational study.帕替西兰治疗伴有多发性神经病的转甲状腺素蛋白淀粉样变:“帕替西兰意大利”多中心观察性研究。
J Neurol. 2025 Feb 15;272(3):209. doi: 10.1007/s00415-025-12950-3.
4
Peripheral Nervous System Involvement of Hereditary Transthyretin Amyloidosis in the United States: A Multi-Center Perspective.美国遗传性转甲状腺素蛋白淀粉样变性的外周神经系统受累:多中心视角
Muscle Nerve. 2025 Aug;72(2):286-293. doi: 10.1002/mus.28414. Epub 2025 May 20.
5
Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags.遗传性和野生型转甲状腺素蛋白淀粉样变性中的多发性神经病:关键临床特征及警示信号的比较
Sci Rep. 2025 Oct 7;15(1):35028. doi: 10.1038/s41598-025-21745-5.
6
Transthyretin variant cerebral amyloid angiopathy fulfilling the modified Boston criteria: Retrospective data from the Bicêtre hospital cohort.符合改良波士顿标准的转甲状腺素蛋白变异型脑淀粉样血管病:比塞特尔医院队列的回顾性数据
Rev Neurol (Paris). 2025 Aug 14. doi: 10.1016/j.neurol.2025.07.012.
7
Transthyretin-related amyloid cardiomyopathy: A single-center experience in southern Poland, an endemic area.转甲状腺素蛋白相关淀粉样心肌病:波兰南部流行地区的单中心经验。
Kardiol Pol. 2025 Jul 11. doi: 10.33963/v.phj.107207.
8
A new screening tool for early recognition of ATTRv polyneuropathy in clinical practice: AmyloScan.一种用于临床实践中早期识别转甲状腺素蛋白淀粉样变性多神经病的新型筛查工具:淀粉样蛋白扫描。
J Neurol. 2025 Sep 4;272(9):608. doi: 10.1007/s00415-025-13338-z.
9
Transthyretin variants impact blood-nerve barrier and neuroinflammation in amyloidotic neuropathy.转甲状腺素蛋白变体影响淀粉样变性神经病中的血神经屏障和神经炎症。
Brain. 2025 Jul 7;148(7):2537-2550. doi: 10.1093/brain/awaf028.
10
A mutation in transthyretin gene in a Mexican patient leading to hereditary amyloidosis: a case report.一名墨西哥患者甲状腺转运蛋白基因突变导致遗传性淀粉样变性:病例报告
J Med Case Rep. 2025 Aug 4;19(1):384. doi: 10.1186/s13256-025-05308-w.

本文引用的文献

1
Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study.对疑似慢性炎症性脱髓鞘性多发性神经病且对静脉注射免疫球蛋白无反应的患者进行遗传性转甲状腺素蛋白淀粉样变性的诊断:一项回顾性研究结果
Orphanet J Rare Dis. 2025 Mar 1;20(1):95. doi: 10.1186/s13023-025-03589-4.
2
Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update.ATTR 淀粉样变的基因型-表型相关性:临床更新。
Heart Fail Clin. 2024 Jul;20(3):317-323. doi: 10.1016/j.hfc.2024.03.006. Epub 2024 Apr 10.
3
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain.
西班牙新发现的遗传性转甲状腺素蛋白淀粉样变病Glu89Lys 变异:表型和临床转归。
Amyloid. 2023 Jun;30(2):199-207. doi: 10.1080/13506129.2022.2142110. Epub 2022 Nov 7.
4
Transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变性。
Cardiovasc Res. 2023 Feb 3;118(18):3517-3535. doi: 10.1093/cvr/cvac119.
5
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.用塔法米迪治疗转甲状腺素蛋白淀粉样心肌病患者的长期生存。
Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20.
6
Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations.当前对转甲状腺素蛋白突变相关脑脊髓液淀粉样变性的综述。
Neurologist. 2021 Sep 7;26(5):189-195. doi: 10.1097/NRL.0000000000000337.
7
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病患者用 patisiran 的长期安全性和疗效:一项开放标签扩展研究的 12 个月结果。
Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16.
8
Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis.波兰人心血管甲状腺素运载蛋白淀粉样变性患者的转甲状腺素蛋白基因突变谱及临床特征。
Cardiol J. 2022;29(6):985-993. doi: 10.5603/CJ.a2020.0104. Epub 2020 Aug 13.
9
Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.遗传性转甲状腺素淀粉样变性患者 inotersen 的长期疗效和安全性的早期数据:来自 NEURO-TTR 试验开放标签扩展的 2 年更新。
Eur J Neurol. 2020 Aug;27(8):1374-1381. doi: 10.1111/ene.14285. Epub 2020 May 29.
10
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.改善多发性神经病ATTR 淀粉样变症诊断的专家共识建议。
J Neurol. 2021 Jun;268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6.